HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in ADC Online Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Prasad, S Search for Related Content PubMed PubMed Citation Articles by Prasad, S Topic Collections Relevant Article

A new paradigm for developing drugs in children: atomoxetine as a model

Correspondence to:
Correspondence to:
Dr S Prasad
Lilly House, Eli Lilly and Company, Priestley Road, Basingstoke, Hampshire RG24 9NL, UK; suyash{at}lilly.com

ABSTRACT
When prescribing drugs for children, it is fundamental to acknowledge that they are distinct from adults with a different physiology and metabolism. They are also still maturing. The development of drugs with a primarily paediatric indication thus requires the trialling of these drugs in a paediatric population to assess safety, tolerability, and efficacy as appropriately as possible. When designing and running a paediatric clinical trial, a number of complexities must be addressed to ensure a successful study, including practical considerations, ethical issues, and tailoring communication appropriately to study participants and parents. The drug development process for atomoxetine, a novel, non-stimulant treatment for attention deficit/hyperactivity disorder (ADHD), encompassed a preclinical programme, initial trials in healthy adults, and a proof of concept trial in adults with ADHD. Open label and placebo controlled studies in paediatric patients followed, thus establishing the drug’s safety and efficacy in children with ADHD. Further trials have addressed, and continue to address, wider aspects of the atomoxetine response in a paediatric setting.

Abbreviations: CSM, Committee on Safety of Medicines; FDA, Food and Drug Administration; MHRA, Medicines and Healthcare Regulatory Agency; NCE, new chemical entity

Relevant Article

Introduction

P Hill
Arch. Dis. Child. 2005 90: i1. [Extract] [Full Text] [PDF]